🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Aaron S. Kesselheim

Brigham and Women's Hospital

ORCID: 0000-0002-8867-2666

Also affiliated with Harvard University

Economics, Econometrics and FinanceBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile
3.2Author DataRank

Indexed papers

4in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

US public investment in development of mRNA covid-19 vaccines: retrospective cohort study

BMJ(2023)10.1136/bmj-2022-073747
Top 7%
3.2DataRank
Top 7%85 citations

Sarosh Nagar, Ameet Sarpatwari, Rachel E. Barenie, Jerry Avorn, Benjamin N. Rome +2 more

Papers

Driven by 19 papers — median percentile 93. Top paper: “US public investment in development of mRNA covid-19 vaccines: retrospective cohort study”.

US public investment in development of mRNA covid-19 vaccines: retrospective cohort study

BMJ(2023)10.1136/bmj-2022-073747
Top 7%
3.2DataRank
Top 7%85 citations

Sarosh Nagar, Ameet Sarpatwari, Rachel E. Barenie, Jerry Avorn, Benjamin N. Rome +2 more

US Food and Drug Administration Approval of New Drugs Based on Noninferiority Trials in Oncology

JAMA Oncology(2019)10.1001/jamaoncol.2019.0093
N/A
0.525DataRank · unranked
11 citations

Aaron S. Kesselheim, Bishal Gyawali

Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020

JAMA Network Open(2022)10.1001/jamanetworkopen.2022.12454
N/A
0.515DataRank · unranked
30 citations

Simon J. Gunter, Aaron S. Kesselheim, Beatrice L. Brown, Krysten W. Joyce, Murray N. Ross +4 more

Cost of Exempting Sole Orphan Drugs From Medicare Negotiation

JAMA Internal Medicine(2024)10.1001/jamainternmed.2023.6293
N/A
0.421DataRank · unranked
11 citations

Olivia Zhao, William B. Feldman, Amitabh Chandra, Aaron S. Kesselheim, Benjamin N. Rome +1 more

Complicated regulatory decision-making following inconsistent trial results: the issue with ibrutinib for mantle cell lymphoma

Nature Reviews Clinical Oncology(2024)10.1038/s41571-023-00821-7
N/A
0.385DataRank · unranked
12 citations

Talal Hilal, Aaron S. Kesselheim, Edward R. Scheffer Cliff

Competition law and pricing among biologic drugs: the case of VEGF therapy for retinal diseases

Journal of Law and the Biosciences(2022)10.1093/jlb/lsac001
N/A
0.345DataRank · unranked
9 citations

Maximilian Hammer, Ravi Parikh, William B. Feldman, Ameet Sarpatwari, Aaron S. Kesselheim +1 more

Insulin access and affordability in the USA: anticipating the first interchangeable insulin product

The Lancet Diabetes & Endocrinology(2020)10.1016/s2213-8587(20)30105-4
N/A
0.312DataRank · unranked
7 citations

Aaron S. Kesselheim, Ameet Sarpatwari, Jing Luo

Prescription Drugs Subject to a Risk Evaluation and Mitigation Strategy: Patient Perspectives on Risk Communication and the Value of Educational Materials

Drug Safety(2025)10.1007/s40264-025-01636-4
N/A
0.104DataRank · unranked
1 citations

Carol Cosenza, Aaron S. Kesselheim, Gita A. Toyserkani, Kate Heinrich Oswell, Cynthia LaCivita +3 more

Trends in Use and Evidence of Adherence to Risk Evaluation and Mitigation Strategy Pregnancy Testing Requirements for Thalidomide, Lenalidomide, and Pomalidomide in the USA, 2000–2020

Drug Safety(2024)10.1007/s40264-024-01443-3
N/A
0DataRank · unranked
6 citations

Ameet Sarpatwari, Krista F. Huybrechts, Joyce Lii, Su Been Lee, Gita A. Toyserkani +6 more

Pharmaceutical access in Brazil: challenges and opportunities

Globalization and Health(2025)10.1186/s12992-025-01141-4
N/A
0DataRank · unranked
5 citations

Ronaldo Portela, Francisco de Assis Acúrcio, Juliana Alvares-Teodoro, Augusto Afonso Guerra, Aaron S. Kesselheim +1 more

Revenue Differences Between Top-Selling Small-Molecule Drugs and Biologics in Medicare

JAMA Health Forum(2025)10.1001/jamahealthforum.2025.4720
N/A
0DataRank · unranked
0 citations

William B. Feldman, Zander Cowan, Benjamin N. Rome, Amitabh Chandra, Aaron S. Kesselheim +2 more

Brand-name market exclusivity for nebulizer therapy to treat asthma and COPD

Nature Biotechnology(2022)10.1038/s41587-022-01451-7
N/A
0DataRank · unranked
7 citations

Doni Bloomfield, Reed F. Beall, Aaron S. Kesselheim, William B. Feldman

Regulatory approval characteristics of antimicrobial versus non-antimicrobial products, 1984–2018: an evaluation of Food and Drug Administration flexibilities

The Lancet Infectious Diseases(2020)10.1016/s1473-3099(20)30197-3
N/A
0DataRank · unranked
3 citations

Mehdi Najafzadeh, Kristina Stefanini, Aaron S. Kesselheim, Jonathan J. Darrow

Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs

JAMA Network Open(2021)10.1001/jamanetworkopen.2021.8816
N/A
0DataRank · unranked
29 citations

William B. Feldman, Rishi Desai, Aaron S. Kesselheim, Benjamin N. Rome

Patents And Regulatory Exclusivities On Inhalers For Asthma And COPD, 1986–2020

Health Affairs(2022)10.1377/hlthaff.2021.01874
N/A
0DataRank · unranked
31 citations

Doni Bloomfield, Reed F. Beall, Aaron S. Kesselheim, William B. Feldman

Experts’ Views on FDA Regulatory Standards for Drug and High-Risk Medical Devices: Implications for Patient Care

Journal of General Internal Medicine(2022)10.1007/s11606-021-07316-0
N/A
0DataRank · unranked
14 citations

Jonathan J. Darrow, Aaron S. Kesselheim, Rita F. Redberg, Sanket S. Dhruva

Differences in Diabetic Prescription Drug Utilization and Costs Among Patients With Diabetes Enrolled in Colorado Marketplace and Medicaid Plans, 2014-2015

JAMA Network Open(2022)10.1001/jamanetworkopen.2021.40371
N/A
0DataRank · unranked
5 citations

Michael S. Sinha, Aditi Bhanja, Heidi Allen, Aaron S. Kesselheim, Benjamin D. Sommers +1 more

Buprenorphine for opioid use disorder: The role of public funding in its development

Drug and Alcohol Dependence(2020)10.1016/j.drugalcdep.2020.108491
N/A
0DataRank · unranked
8 citations

Aaron S. Kesselheim, Rachel E. Barenie

The impact of electronic health record discontinuity on prediction modeling

PLoS ONE(2023)10.1371/journal.pone.0287985
N/A
0DataRank · unranked
3 citations

Lily G. Bessette, Richard Wyss, Aaron S. Kesselheim, Kueiyu Joshua Lin, Shreyas Kar